IS7792A - Hýdantóínafleiður og notkun þeirra sem TACE hemla - Google Patents
Hýdantóínafleiður og notkun þeirra sem TACE hemlaInfo
- Publication number
- IS7792A IS7792A IS7792A IS7792A IS7792A IS 7792 A IS7792 A IS 7792A IS 7792 A IS7792 A IS 7792A IS 7792 A IS7792 A IS 7792A IS 7792 A IS7792 A IS 7792A
- Authority
- IS
- Iceland
- Prior art keywords
- hydantoin derivatives
- tace inhibitors
- tace
- inhibitors
- hydantoin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0221246.2A GB0221246D0 (en) | 2002-09-13 | 2002-09-13 | Compounds |
PCT/GB2003/003914 WO2004024721A1 (en) | 2002-09-13 | 2003-09-09 | Hydantoin derivatives und deren verwendung als tace inhibitoren |
Publications (1)
Publication Number | Publication Date |
---|---|
IS7792A true IS7792A (is) | 2005-04-11 |
Family
ID=9943999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS7792A IS7792A (is) | 2002-09-13 | 2005-04-11 | Hýdantóínafleiður og notkun þeirra sem TACE hemla |
Country Status (19)
Country | Link |
---|---|
US (2) | US20050256176A1 (is) |
EP (2) | EP1539740A1 (is) |
JP (2) | JP2006503829A (is) |
KR (1) | KR20050042499A (is) |
CN (1) | CN1681804A (is) |
AR (2) | AR043049A1 (is) |
AU (2) | AU2003263345A1 (is) |
BR (1) | BR0314275A (is) |
CA (1) | CA2497571A1 (is) |
GB (1) | GB0221246D0 (is) |
IS (1) | IS7792A (is) |
MX (1) | MXPA05002602A (is) |
NO (1) | NO20051788L (is) |
PL (1) | PL375877A1 (is) |
RU (1) | RU2005106353A (is) |
TW (2) | TW200409769A (is) |
UY (1) | UY27972A1 (is) |
WO (2) | WO2004024715A1 (is) |
ZA (1) | ZA200501677B (is) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0100902D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
SE0100903D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
SE0103710D0 (sv) | 2001-11-07 | 2001-11-07 | Astrazeneca Ab | Compounds |
SE0202539D0 (sv) | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
GB0221246D0 (en) * | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
US7132432B2 (en) * | 2003-06-05 | 2006-11-07 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) |
WO2005000309A2 (en) * | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
GB0405101D0 (en) * | 2004-03-06 | 2004-04-07 | Astrazeneca Ab | Compounds |
US7696234B2 (en) | 2004-06-02 | 2010-04-13 | Eli Lilly And Company | Histamine H3 receptor agents, preparation and therapeutic uses |
US7648992B2 (en) | 2004-07-05 | 2010-01-19 | Astrazeneca Ab | Hydantoin derivatives for the treatment of obstructive airway diseases |
SE0401763D0 (sv) * | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Compounds |
SE0401762D0 (sv) * | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Novel compounds |
US7488745B2 (en) | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
AR050169A1 (es) | 2004-07-16 | 2006-10-04 | Schering Corp | Compuesto para el tratamiento de trastornos inflamatorios |
US7504424B2 (en) | 2004-07-16 | 2009-03-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
SE0403086D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
SE0403085D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
AR059036A1 (es) | 2006-01-17 | 2008-03-12 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
US7612212B2 (en) | 2006-02-22 | 2009-11-03 | Hoffmann-La Roche Inc. | Substituted hydantoins |
TW200740769A (en) * | 2006-03-16 | 2007-11-01 | Astrazeneca Ab | Novel process |
ATE509956T1 (de) * | 2006-06-08 | 2011-06-15 | Helmholtz Zentrum Muenchen | Spezifische proteaseinhibitoren und ihre verwendung in der krebstherapie |
CA2655881A1 (en) * | 2006-06-28 | 2008-01-03 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of atorvastatin |
TW200831488A (en) * | 2006-11-29 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
WO2010008894A1 (en) * | 2008-06-24 | 2010-01-21 | Valeant Pharmaceuticals International | Benzyloxy anilide derivatives useful as potassium channel modulators |
TW201024303A (en) | 2008-09-24 | 2010-07-01 | Schering Corp | Compounds for the treatment of inflammatory disorders |
AR073307A1 (es) | 2008-09-24 | 2010-10-28 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
EP2356111A1 (en) | 2008-11-10 | 2011-08-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
WO2010054278A2 (en) | 2008-11-10 | 2010-05-14 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
CA2858164C (en) * | 2011-12-09 | 2020-12-15 | Kaken Pharmaceutical Co., Ltd. | Pyridone derivative and pharmaceutical containing same |
US9809571B2 (en) | 2013-01-07 | 2017-11-07 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
KR102321814B1 (ko) | 2013-06-07 | 2021-11-05 | 가껭세이야꾸가부시기가이샤 | (+)-5-(3,4-디플루오로페닐)-5-[(3-메틸-2-옥소피리딘-1(2h)-일)메틸]이미다졸리딘-2,4-디온 및 그것을 함유하는 의약 |
EA037990B1 (ru) | 2015-07-08 | 2021-06-21 | Св6 Терапьютикс (Най) Лимитед | Ингибиторы дезоксиуридинтрифосфатазы, содержащие гидантоин |
US10570100B2 (en) | 2015-07-08 | 2020-02-25 | University Of Southern California | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage |
WO2017006270A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
WO2017006283A1 (en) | 2015-07-08 | 2017-01-12 | Cv6 Therapeutics (Ni) Limited | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage |
WO2018098209A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Amino sulfonyl compounds |
WO2018098204A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | 6-membered uracil isosteres |
US11014924B2 (en) | 2016-11-23 | 2021-05-25 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
WO2018098206A1 (en) * | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
WO2018098208A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Nitrogen ring linked deoxyuridine triphosphatase inhibitors |
US11247984B2 (en) | 2017-01-05 | 2022-02-15 | Cv6 Therapeutics (Ni) Limited | Uracil containing compounds |
EP3822268A1 (en) | 2019-11-15 | 2021-05-19 | Bayer Aktiengesellschaft | Substituted hydantoinamides as adamts7 antagonists |
EP3822265A1 (en) | 2019-11-15 | 2021-05-19 | Bayer AG | Substituted hydantoinamides as adamts7 antagonists |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2745875A (en) * | 1953-06-30 | 1956-05-15 | Hoechst Ag | Preparation of nu-acylamino-phenylpropane diols |
US3452040A (en) * | 1966-01-05 | 1969-06-24 | American Home Prod | 5,5-disubstituted hydantoins |
US3529019A (en) * | 1968-04-23 | 1970-09-15 | Colgate Palmolive Co | Alkylaryloxy alanines |
US3849574A (en) * | 1971-05-24 | 1974-11-19 | Colgate Palmolive Co | Alpha-substituted-beta-arylthioalkyl amino-acids,for increasing heart rate |
US4315031A (en) * | 1977-09-01 | 1982-02-09 | Science Union Et Cie | Thiosubstituted amino acids |
GB1601310A (en) * | 1978-05-23 | 1981-10-28 | Lilly Industries Ltd | Aryl hydantoins |
JPS61212292A (ja) * | 1985-03-19 | 1986-09-20 | Mitsui Toatsu Chem Inc | D−α−アミノ酸の製造方法 |
PH31245A (en) * | 1991-10-30 | 1998-06-18 | Janssen Pharmaceutica Nv | 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives. |
US5308853A (en) * | 1991-12-20 | 1994-05-03 | Warner-Lambert Company | Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties |
US5246943A (en) * | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
US6166041A (en) * | 1995-10-11 | 2000-12-26 | Euro-Celtique, S.A. | 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma |
EP0874842B1 (en) * | 1995-11-22 | 2002-04-10 | Darwin Discovery Limited | Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (mmp) and/or tumour necrosis factor (tnf) |
GB9616643D0 (en) * | 1996-08-08 | 1996-09-25 | Chiroscience Ltd | Compounds |
US5919790A (en) * | 1996-10-11 | 1999-07-06 | Warner-Lambert Company | Hydroxamate inhibitors of interleukin-1β converting enzyme |
US5804593A (en) * | 1996-10-22 | 1998-09-08 | Pharmacia & Upjohn Company | α-Amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors |
EP0983239A1 (en) * | 1997-05-06 | 2000-03-08 | Novo Nordisk A/S | Novel heterocyclic compounds |
DE59802394D1 (de) * | 1997-05-09 | 2002-01-24 | Hoechst Ag | Substituierte Diaminocarbonsäuren |
NZ505968A (en) * | 1998-02-04 | 2003-03-28 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix- degrading metallproteinases |
US6329418B1 (en) * | 1998-04-14 | 2001-12-11 | The Procter & Gamble Company | Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
AU4074799A (en) * | 1998-05-14 | 1999-11-29 | Du Pont Pharmaceuticals Company | Substituted aryl hydroxamic acids as metalloproteinase inhibitors |
US6429213B1 (en) * | 1998-06-17 | 2002-08-06 | Bristol Myers Squibb Pharma Co | Cyclic hydroxamic acids as metalloproteinase inhibitors |
US6339101B1 (en) * | 1998-08-14 | 2002-01-15 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders |
DE69915004T2 (de) * | 1998-11-05 | 2004-09-09 | Pfizer Products Inc., Groton | 5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate |
US6340691B1 (en) * | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
CN1373662A (zh) * | 1999-08-12 | 2002-10-09 | 法玛西雅意大利公司 | 3(5)-氨基-吡唑衍生物、其制备方法及其用作抗肿瘤剂的用途 |
US6525202B2 (en) * | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
US20020091107A1 (en) * | 2000-09-08 | 2002-07-11 | Madar David J. | Oxazolidinone antibacterial agents |
DE10047073C1 (de) * | 2000-09-22 | 2002-01-24 | Dbt Gmbh | Hydraulisch schaltbares Wegeventil |
SK10932003A3 (sk) * | 2001-03-15 | 2004-04-06 | Astrazeneca Ab | Metaloproteinázové inhibítory |
SE0100903D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
SE0100902D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
ATE445400T1 (de) * | 2001-05-25 | 2009-10-15 | Bristol Myers Squibb Co | Hydantion-derivate als hemmer von matrix- metalloproteinasen |
SE0103710D0 (sv) * | 2001-11-07 | 2001-11-07 | Astrazeneca Ab | Compounds |
SE0202539D0 (sv) * | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
GB0221246D0 (en) * | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
TWI220073B (en) * | 2003-07-24 | 2004-08-01 | Au Optronics Corp | Method for manufacturing polysilicon film |
-
2002
- 2002-09-13 GB GBGB0221246.2A patent/GB0221246D0/en not_active Ceased
-
2003
- 2003-09-05 TW TW092124627A patent/TW200409769A/zh unknown
- 2003-09-05 TW TW092124646A patent/TW200406398A/zh unknown
- 2003-09-09 AU AU2003263345A patent/AU2003263345A1/en not_active Abandoned
- 2003-09-09 PL PL03375877A patent/PL375877A1/xx not_active Application Discontinuation
- 2003-09-09 KR KR1020057004211A patent/KR20050042499A/ko not_active Application Discontinuation
- 2003-09-09 US US10/527,349 patent/US20050256176A1/en not_active Abandoned
- 2003-09-09 MX MXPA05002602A patent/MXPA05002602A/es not_active Application Discontinuation
- 2003-09-09 EP EP03795072A patent/EP1539740A1/en not_active Withdrawn
- 2003-09-09 JP JP2004535650A patent/JP2006503829A/ja active Pending
- 2003-09-09 CA CA002497571A patent/CA2497571A1/en not_active Abandoned
- 2003-09-09 AU AU2003263347A patent/AU2003263347A1/en not_active Abandoned
- 2003-09-09 CN CNA038219557A patent/CN1681804A/zh active Pending
- 2003-09-09 EP EP03795075A patent/EP1551826A1/en not_active Withdrawn
- 2003-09-09 JP JP2004535653A patent/JP2006507248A/ja active Pending
- 2003-09-09 US US10/527,215 patent/US20060063818A1/en not_active Abandoned
- 2003-09-09 BR BR0314275-2A patent/BR0314275A/pt not_active Application Discontinuation
- 2003-09-09 WO PCT/GB2003/003907 patent/WO2004024715A1/en not_active Application Discontinuation
- 2003-09-09 RU RU2005106353/04A patent/RU2005106353A/ru not_active Application Discontinuation
- 2003-09-09 WO PCT/GB2003/003914 patent/WO2004024721A1/en not_active Application Discontinuation
- 2003-09-11 UY UY27972A patent/UY27972A1/es not_active Application Discontinuation
- 2003-09-12 AR ARP030103319A patent/AR043049A1/es unknown
- 2003-09-12 AR ARP030103317A patent/AR041250A1/es unknown
-
2005
- 2005-02-25 ZA ZA200501677A patent/ZA200501677B/xx unknown
- 2005-04-11 IS IS7792A patent/IS7792A/is unknown
- 2005-04-12 NO NO20051788A patent/NO20051788L/no unknown
Also Published As
Publication number | Publication date |
---|---|
TW200406398A (en) | 2004-05-01 |
AR041250A1 (es) | 2005-05-11 |
CA2497571A1 (en) | 2004-03-25 |
BR0314275A (pt) | 2005-08-09 |
ZA200501677B (en) | 2005-09-12 |
CN1681804A (zh) | 2005-10-12 |
EP1539740A1 (en) | 2005-06-15 |
KR20050042499A (ko) | 2005-05-09 |
TW200409769A (en) | 2004-06-16 |
JP2006503829A (ja) | 2006-02-02 |
US20060063818A1 (en) | 2006-03-23 |
JP2006507248A (ja) | 2006-03-02 |
MXPA05002602A (es) | 2005-05-05 |
EP1551826A1 (en) | 2005-07-13 |
WO2004024721A1 (en) | 2004-03-25 |
PL375877A1 (en) | 2005-12-12 |
NO20051788L (no) | 2005-06-13 |
US20050256176A1 (en) | 2005-11-17 |
WO2004024715A1 (en) | 2004-03-25 |
AR043049A1 (es) | 2005-07-13 |
AU2003263347A1 (en) | 2004-04-30 |
AU2003263345A1 (en) | 2004-04-30 |
GB0221246D0 (en) | 2002-10-23 |
RU2005106353A (ru) | 2005-10-10 |
UY27972A1 (es) | 2004-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS7792A (is) | Hýdantóínafleiður og notkun þeirra sem TACE hemla | |
IS2529B (is) | Nýjar spírótrísýklískar afleiður og notkun þeirra sem fosfódíesterasa-7-hindrar | |
IS7717A (is) | Pýrídasínónafleiður sem PDF4-hemlar | |
IS7700A (is) | Ný spíróþétt kínasólínón og notkun þeirra sem fosfórdíesterasa hindrar | |
DK1648426T3 (da) | Benzimidazolderivater og anvendelse heraf som proteinkinaseinhibitorer | |
IS6656A (is) | Útskiptar kínasólínafleiður og notkun þeirra sem hemla | |
DE60320933D1 (de) | Rho-kinase inhibitoren | |
IS7620A (is) | Qínólín afleiður og notkun þeirra sem tálma sveppagerla | |
IS7434A (is) | N-amínóasetýl-pýrrólídín-2-karbónítríl og notkun þeirra sem DDP-IV tálma | |
NO20053356D0 (no) | Aminindazolderivater og anvendelse derav som kinaseinhibitorer. | |
DE60319430D1 (de) | R- und fgfr-inhibitoren | |
ATE505471T1 (de) | Azaindol-kinaseinhibitoren | |
NO20044617L (no) | Substituerte benzazoler og anvendelse derav som RAF kinaseinbibitorer | |
HK1077762A1 (zh) | TFGß[轉化生長因子]的抑制劑 | |
DK1592686T3 (da) | Gyrase-inhibitorer og anvendelser deraf | |
DE60306904D1 (de) | Selektive dipeptidische inhibitoren von kallikrein | |
IS8381A (is) | 2-pýridónafleiður sem daufkyrningselastasatálmar og notkun þeirra | |
IS7749A (is) | Pýrimídínafleiður og notkun þeirra sem CB2 beina | |
IS7509A (is) | Þíoxantínafleiður sem mergperoxídasatálmar | |
AU2003232848A8 (en) | Phenylaminopyrimidines and their use as rho-kinase inhibitors | |
IL165475A0 (en) | Nitrooxyderivatives of eyclooxygenase-2 inhibitors | |
AU2003215756A8 (en) | Benzimidazoles and their use as mitogen-activated- and rho-kinase inhibitors | |
ATE402700T1 (de) | Glycinamid-derivate als raf-kinase-hemmer | |
PL371217A1 (en) | Inhibitors of integrin alphavbeta6 | |
IS7666A (is) | N-súlfónýlpíperídín sem málmprótínkljúfatálmar (TACE) |